Tibor KELER,Joel GOLDSTEIN,Lizhen HE,Henry C. MARSH,Karuna SUNDARAPANDIYAN,Lawrence J. THOMAS,Laura A. VITALE,Jenifer WIDGER
申请号：
US15557035
公开号：
US20180044429A1
申请日:
2016.03.09
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
